%0 Journal Article
%T Evaluation for clinical and prognostic implications of glypican-3 and ¦Á-fetoprotein in hepatocellular carcinoma: a new subtype?
%A Dan Li
%A Lin Ye
%A Xiaolong Yu
%A Yaobing Chen
%J SCIE-indexed Journal
%D 2020
%R 10.21037/tcr-19-1803
%X Globally, liver cancer ranked sixth for cancer incidence and fourth for cancer deaths in 2015 (1). Most primary liver cancers (70¨C90%) occurring worldwide are hepatocellular carcinoma (HCC) (2). Hepatitis B virus (HBV) and hepatitis C virus (HCV) account for an estimated 32% of infection-related cancer cases, mostly liver cancer, in less-developed countries and 19% in more developed countries (3). Until now, different studies have identified on the molecular level that the expressions of some proteins, such as CD133, OV6, CD44, CD47, CK19, EpCAM, and especially ¦Á-fetoprotein (AFP) and glypican-3 (GPC3), are closely associated with the recurrence and survival of HCC patients (4-8). Although great progress has been made in HCC treatment, including curative surgery and nonsurgical treatment, the HCC prognosis remains poor (9). This may be due to the subtype classification based on only one protein, which may be not sufficient to clarify the diagnosis and prognosis of malignant HCC. Consequently, a more precise subtype classification is required to assess HCC patients
%U http://tcr.amegroups.com/article/view/38459/html